A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies (NCT05453903)

🧪 Interventions in This Study

• Bleximenib (DRUG)
• Venetoclax (VEN) (DRUG)
• Azacitidine (AZA) (DRUG)
• Cytarabine (DRUG)
• Daunorubicin or Idarubicin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (32 Sites)

Showing the first 25 of 32 sites.

• The University of Alabama at Birmingham — Birmingham, Alabama
• City of Hope — Duarte, California
• Massachusetts General Hospital — Boston, Massachusetts
• Albert Einstein College Of Medicine — New York, New York
• Novant Health — Charlotte, North Carolina
• Novant Health Forsyth Medical Center — Winston-Salem, North Carolina
• MD Anderson — Houston, Texas
• Monash Medical Centre — Clayton,
• Peter MacCallum Cancer Centre — Melbourne,
• Westmead Hospital — Westmead,
• Princess Margaret Cancer Centre University Health Network — Toronto, Ontario
• Institut Paoli Calmettes — Marseille,
• Chu Rennes Hopital Pontchaillou — Rennes,
• Institut Universitaire du Cancer Toulouse Oncopole — Toulouse,
• CHU de Tours - Hôpital de Bretonneau — Tours,
• Charite Universitaetsmedizin Berlin — Berlin,
• Universitatsklinikum Carl Gustav Carus Dresden — Dresden,
• Universitaetsklinikum Heidelberg — Heidelberg,
• Universitaetsklinikum Leipzig — Leipzig,
• Universitatsklinikum Ulm — Ulm,
• Azienda Opedaliero-Universitaria Policlinico Sant'orsola Malpighi di Bologna — Bologna,
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori — Meldola,
• ASST Grande Ospedale Metropolitano Niguarda — Milan,
• IRCCS Istituto Clinico Humanitas — Rozzano,
• Hosp Clinic de Barcelona — Barcelona,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Leukemia, Myeloid, Acute

• A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — Gilbert, Arizona
• Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia — Duarte, California
• A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy — Duarte, California
• A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms — Calgary, Alberta
• Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) — Houston, Texas

Explore by condition: All Leukemia, Myeloid, Acute clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.